Aadi Bioscience (Aadi Bioscience) Interest Coverage : 0 (At Loss) (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Aadi Bioscience's Operating Income for the three months ended in Dec. 2023 was $-17.71 Mil. Aadi Bioscience's Interest Expense for the three months ended in Dec. 2023 was $-0.06 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Aadi Bioscience's Interest Coverage or its related term are showing as below:

AADI's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 137.02
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Aadi Bioscience Interest Coverage Historical Data

The historical data trend for Aadi Bioscience's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Aadi Bioscience Interest Coverage Chart

Aadi Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Coverage

Aadi Bioscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Aadi Bioscience's Interest Coverage

For the Biotechnology subindustry, Aadi Bioscience's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aadi Bioscience's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aadi Bioscience's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Aadi Bioscience's Interest Coverage falls into.

Aadi Bioscience Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Aadi Bioscience's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Aadi Bioscience's Interest Expense was $-0.23 Mil. Its Operating Income was $-71.93 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.83 Mil.

Aadi Bioscience did not have earnings to cover the interest expense.

Aadi Bioscience's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Aadi Bioscience's Interest Expense was $-0.06 Mil. Its Operating Income was $-17.71 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.83 Mil.

Aadi Bioscience did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Aadi Bioscience (NAS:AADI) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Aadi Bioscience Interest Coverage Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Aadi Bioscience (Aadi Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (NAS:AADI) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

3350:Germany

Address

17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272

Website

https://www.aadibio.com

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Executives

Neil Desai	director, officer: See Remarks	C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
David James Lennon	director, officer: Chief Executive Officer	C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD, SUITE A250, PACIFIC PALISADES CA 90272
Mohammad Hirmand	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Scott M. Giacobello	officer: Chief Financial Officer	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Lorettta M Itri	officer: Chief Medical Officer
Brendan Delaney	officer: Chief Operating Officer	300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Emma Reeve	director	C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Karin M. Hehenberger	director	C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON CO 01803
Richard E Maroun	director	C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Caley Castelein	director	THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Lance E Thibault	officer: Chief Financial Officer
Behzad Aghazadeh	director, other: See Remarks	C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Venbio Select Advisor Llc	director, other: See Remarks	110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Anupam Dalal	director	88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Avoro Ventures Llc	director, other: See Remarks	110 GREEN STREET, SUITE 800, NEW YORK NY 10012